Alnylam Pharmaceuticals
ALNY
#581
Rank
$35.78 B
Marketcap
$277.43
Share price
1.91%
Change (1 day)
71.37%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -$0.19 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are $2.09 Billion USD. In 2023 the company made an earning of -$0.32 Billion USD, an increase over its 2022 earnings that were of -$0.98 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -$0.19 Billion-40.16%
2023 -$0.32 Billion-67.84%
2022 -$0.98 Billion36.93%
2021 -$0.71 Billion-8.04%
2020 -$0.78 Billion-15.66%
2019 -$0.92 Billion12.23%
2018 -$0.82 Billion62.91%
2017 -$0.51 Billion17.78%
2016 -$0.43 Billion43.44%
2015 -$0.3 Billion60.69%
2014 -$0.19 Billion98.2%
2013 -$92.95 Million
2011 -$54.82 Million27.48%
2010 -$43.01 Million-10.92%
2009 -$48.28 Million95.77%
2008 -$24.66 Million
2006 -$39.51 Million-9.13%
2005 -$43.48 Million34.74%
2004 -$32.27 Million36.79%
2003 -$23.59 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-$0.53 Billion 181.30%๐Ÿ‡บ๐Ÿ‡ธ USA
$4.96 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
$62.22 M-133.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.25 Billion 30.91%๐Ÿ‡บ๐Ÿ‡ธ USA
-$35 Million-81.27%๐Ÿ‡บ๐Ÿ‡ธ USA
$12.73 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$7.40 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
$0.82 B-542.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel